Results 31 to 40 of about 415,351 (305)

Risk factors and markers of inflammation of comorbid allergic diseases: rhinitis and bronchial asthma

open access: yesАллергология и Иммунология в Педиатрии, 2023
Introduction. Today there has been a steady increase in the allergic pathology of the respiratory tract - bronchial asthma and allergic rhinitis in pediatric practice.
R. Z. Tikhonova, R. M. Fayzullina
doaj   +1 more source

Risk factors for asthma and allergy associated with urban migration: background and methodology of a cross-sectional study in Afro-Ecuadorian school children in Northeastern Ecuador (Esmeraldas-SCAALA Study). [PDF]

open access: yes, 2006
BACKGROUND: Asthma and allergic diseases are becoming increasingly frequent in children in urban centres of Latin America although the prevalence of allergic disease is still low in rural areas.
Cooper Philip J   +51 more
core   +2 more sources

Host lipidome analysis during rhinovirus replication in HBECs identifies potential therapeutic targets

open access: yesJournal of Lipid Research, 2018
In patients with asthma or chronic obstructive pulmonary disease, rhinovirus (RV) infections can provoke acute worsening of disease, and limited treatment options exist.
An Nguyen   +8 more
doaj   +1 more source

Thrombocytopoesis in allergic asthma

open access: yesPolish Archives of Internal Medicine, 2007
Allergic asthma is characterized by bronchial inflammation and simultaneous repair processes that results in increased airway obstruction. Recent studies indicate that platelets could play an important role in this process.The aim of the present study was to evaluate the platelet count, the percentage of reticulated platelets, plasma thrombopoietin and
Izabela, Kemona-Chetnik   +4 more
openaire   +2 more sources

Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies

open access: yesMayo Clinic Proceedings: Innovations, Quality & Outcomes, 2022
Objective: To estimate the potential risk for a future postmarket black box warning (BBW) of US Food and Drug Administration (FDA)-approved monoclonal antibodies (mAbs) because of the importance for medical clinicians to understand mAb risks and benefits,
John B. Hagan, MD   +4 more
doaj   +1 more source

Siblings, asthma, rhinoconjunctivitis and eczema: a worldwide perspective from the International Study of Asthma and Allergies in Childhood. [PDF]

open access: yes, 2015
BACKGROUND: Associations of larger families with lower prevalences of hay fever, eczema and objective markers of allergic sensitization have been found fairly consistently in affluent countries, but little is known about these relationships in less ...
Strachan, DP   +17 more
core   +1 more source

Pediatric Selective IgM Immunodeficiency

open access: yesClinical and Developmental Immunology, 2008
Objective. Limited information exists on features of pediatric Selective IgM immunodeficiency (SIgMID). Previously published pediatric cases and 2 new cases are reviewed. Methods.
Marc F. Goldstein   +5 more
doaj   +1 more source

The discovery of potent, selective, and reversible inhibitors of the house dust mite peptidase allergen Der p 1: an innovative approach to the treatment of allergic asthma. [PDF]

open access: yes, 2014
Blocking the bioactivity of allergens is conceptually attractive as a small-molecule therapy for allergic diseases but has not been attempted previously.
Newton, GK   +14 more
core   +1 more source

United Kingdom Oscillation Study: long-term outcomes of a randomised trial of two modes of neonatal ventilation

open access: yesHealth Technology Assessment, 2014
Background: One in 200 infants in the UK is born extremely prematurely, i.e. before 29 weeks of gestation. Seventy-five per cent of such infants survive, but many have long-term respiratory and/or functional problems.
Anne Greenough   +6 more
doaj   +1 more source

Allergen Immunotherapy in Asthma

open access: yesPathogens, 2021
Allergen immunotherapy (AIT) is a specific treatment involving the administration of relevant allergens to allergic patients, with subtypes including subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT).
Kazuyuki Nakagome, Makoto Nagata
doaj   +1 more source

Home - About - Disclaimer - Privacy